Studies have demonstrated a significant association between 18F-FDOPA uptake and key molecular features of GBM, such as isocitrate dehydrogenase (IDH) mutations, the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, and epidermal growth factor receptor (EGFR) amplification [56,57]. The gene discussed is MGMT; the disease is glioblastoma.